Edition:
United States

Steadymed Ltd (STDY.OQ)

STDY.OQ on NASDAQ Stock Exchange Global Market

4.60USD
23 May 2018
Change (% chg)

$-0.05 (-1.08%)
Prev Close
$4.65
Open
$4.60
Day's High
$4.60
Day's Low
$4.55
Volume
207,685
Avg. Vol
14,438
52-wk High
$7.30
52-wk Low
$2.65

Chart for

About

SteadyMed Ltd. is a specialty pharmaceutical company. The Company is focused on the development and commercialization of various therapeutic product candidates. Its primary focus is to obtain approval in the United States for the sale of Trevyent for the treatment of pulmonary arterial hypertension (PAH). It is also developing... (more)

Overall

Beta: --
Market Cap(Mil.): $122.90
Shares Outstanding(Mil.): 26.57
Dividend: --
Yield (%): --

Financials

  STDY.OQ Industry Sector
P/E (TTM): -- 237.88 32.90
EPS (TTM): -1.15 -- --
ROI: -80.66 -7.38 12.74
ROE: -121.74 -10.11 14.64

BRIEF-SteadyMed Reports Q1 Loss Per Share Of $0.39

* STEADYMED PROVIDES CORPORATE UPDATE AND REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS

May 15 2018

BRIEF-United Therapeutics To Acquire SteadyMed Ltd

* UNITED THERAPEUTICS-TRANSACTION, INCLUDING $75 MILLION IN CONTINGENT CONSIDERATION, IS VALUED AT $216 MILLION

Apr 30 2018

BRIEF-United Therapeutics To Acquire SteadyMed For $4.46 Per Share In Cash

* STEADYMED - DEAL INCLUDES ADDITIONAL $2.63/SHARE IN CASH TO UNITED THERAPEUTICS UPON ACHIEVEMENT OF MILESTONE RELATED TO COMMERCIALIZATION OF TREVYENT

Apr 30 2018

BRIEF-Steadymed Reports Q4 Loss Per Share $0.22

* Q4 LOSS PER SHARE $0.22 Source text : http://bit.ly/2Gov1vO Further company coverage:

Mar 30 2018

BRIEF-SteadyMed Announces FDA Agreed Pathway To Trevyent NDA Resubmission

* STEADYMED ANNOUNCES FDA AGREED PATHWAY TO TREVYENT NDA RESUBMISSION

Dec 08 2017

Earnings vs. Estimates